Related Experiment Videos
Clinical trials with gugulipid. A new hypolipidaemic agent
Summary
Gugulipid significantly lowers cholesterol and triglycerides in patients. This herbal remedy showed comparable efficacy to clofibrate, with added benefits for HDL-cholesterol.
Area of Science:
- Cardiovascular Pharmacology
- Natural Product Therapeutics
Background:
- Dyslipidemia is a major risk factor for cardiovascular disease.
- Herbal remedies like gugulipid are explored for lipid-lowering effects.
Purpose of the Study:
- To evaluate the efficacy and safety of gugulipid in managing dyslipidemia.
- To compare gugulipid's lipid-lowering effects with clofibrate.
Main Methods:
- Multicentric open-label trial with 205 patients on gugulipid (500 mg tds).
- Double-blind, crossover study comparing gugulipid (n=125) and clofibrate (n=108).
- Lipid profiles (cholesterol, triglycerides, HDL-C, LDL-C) were monitored.
Main Results:
- Gugulipid significantly reduced serum cholesterol (avg. 23.6%) and triglycerides (avg. 22.6%) in 70-80% of patients during the open trial.
- In the crossover study, gugulipid lowered cholesterol by 11% and triglycerides by 16.8%, comparable to clofibrate (10% and 21.6%).
- Gugulipid increased HDL-cholesterol in 60% of responders, while clofibrate had no effect. Both drugs decreased LDL-cholesterol.
Conclusions:
- Gugulipid demonstrates significant lipid-lowering efficacy and is well-tolerated.
- It offers a potential alternative to synthetic drugs like clofibrate, particularly for improving HDL-cholesterol levels.